23andMe's Fall
23andMe’s collapse from a multibillion‑dollar SPAC valuation to a penny stock is prompting scrutiny of its core business model: a mostly one‑time consumer DNA test subsidized by hopes of monetizing genetic data. Commenters highlight strategic missteps in drug development, a controversial shift to subscriptions, and a major data breach, while debating how valuable 23andMe’s genetic database really is to pharma and how dangerous it could become if sold off in bankruptcy. Many are now focused on privacy risks and the fate of customers’ DNA data if the company is acquired or liquidated.
Business model & funding
- Many see 23andMe’s core problem as selling a mostly one‑time test while trying to build a recurring‑revenue, “comprehensive healthcare / drug company” narrative.
- Ambitious plans to discover and develop drugs are widely viewed as unrealistic for a cash‑burning company without deep pharma capabilities or capital.
- The GSK partnership is discussed as a key bet: started as a large equity + exclusive co‑funded R&D deal, later reduced to a small, non‑exclusive data license where GSK owns new programs outright, suggesting the original thesis under‑delivered.
- Commenters tie the story to ZIRP/cheap‑money VC: big valuations via SPAC and elite connections, weak path to sustainable profit.
Data value & scientific limits
- Debate over how valuable their dataset really is:
- Pro: large, research‑grade genotyping array; useful for target discovery and population genetics; comparable to other respected genetics platforms.
- Con: SNP arrays only cover common variants; limited phenotypic/clinical data; rare variants and deep clinical context matter more for many diseases/drugs.
- Some argue the strongest realistic use is trial design/enrichment or target discovery, not full drug development.
Privacy, security & legal concerns
- Serious worry that, if the company fails or is sold, DNA and survey data could end up with private equity, data brokers, insurers, or government/defense contractors.
- Several note that in bankruptcy data are treated as assets and may have to be preserved and sold; existing promises could be voided by trustees.
- HIPAA generally doesn’t apply because 23andMe isn’t a covered healthcare entity; other laws (GINA, state rules) offer partial protection but have gaps.
- Recent breach involved account takeover and scraping of ancestry/social data; encryption at rest would not have helped. Raw‑data downloads are “temporarily” disabled, prompting suspicion they’re trying to stem data exfiltration.
User experience & product choices
- Mixed personal outcomes: some report life‑changing discoveries (finding unknown parents/siblings, actionable mutations); others got trivial or inaccurate trait/health estimates.
- Many feel betrayed by the pivot to 23andMe+ subscriptions after contributing detailed research surveys, and by risk‑averse, slow, shallow health reporting versus third‑party tools.
- Acquisition of a telehealth “penis pill” outfit is viewed as brand‑damaging and symptomatic of a flailing strategy.
Broader reflections
- Frequent comparisons to Theranos’ hype (though 23andMe’s tech basically works) and to a “steroid era” of tech where connections and storytelling trumped durable business models.
- Some call for stronger laws: time‑limited data licenses, stricter genetic‑privacy regulation, or mandatory deletion on shutdown—currently seen as aspirational and unclear.